Ivermectin for COVID-19 patients [Ivermectina para pacientes COVID-19]
DOI:
https://doi.org/10.5281/zenodo.10607357Keywords:
ivermectin, covid-19, antibodiesAbstract
Objective: to analyse the efficacy of ivermectin as an alternative treatment for patients affected by COVID-19. Methods: A descriptive literature review was conducted. Results and conclusion: Patients randomised to receive ivermectin, placebo or another intervention suggest that a five-day course of ivermectin was safe and showed some efficacy in the treatment of adult patients with mild COVID-19. Although the rate of primary outcome events was slightly lower in the ivermectin group compared to the placebo group, the difference did not reach statistical significance. Of note, adverse events were not significantly different between the ivermectin and placebo groups. These findings are promising but indicate the need for larger trials and further studies to confirm and deepen the understanding of the efficacy and safety of ivermectin in the context of COVID-19.
Downloads
References
Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial [published correction appears in JAMA. 2023 Jan 10;329(2):178] [published correction appears in JAMA. 2023 Aug 15;330(7):666]. JAMA. 2022;328(16):1595-1603. doi:10.1001/jama.2022.18590
Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;28(4):e434-e460. Published 2021 Jun 21. doi:10.1097/MJT.0000000000001402
Bartoletti M, Azap O, Barac A, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022;28(2):222-238. doi:10.1016/j.cmi.2021.11.007
Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022;387(7):599-610. doi:10.1056/NEJMoa2201662
Parise R, Deruiter J, Ren J, et al. Impact of COVID-19 therapy on hyperglycemia. Diab Vasc Dis Res. 2022;19(3):14791641221095091. doi:10.1177/14791641221095091
Schwalb A, Armyra E, Méndez-Aranda M, Ugarte-Gil C. COVID-19 in Latin America and the Caribbean: Two years of the pandemic. J Intern Med. 2022;292(3):409-427. doi:10.1111/joim.13499
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi:10.1016/j.antiviral.2020.104787
Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. doi:10.4269/ajtmh.20-0271
Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Res. 2020;178:104805. doi:10.1016/j.antiviral.2020.104805
Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):23. Published 2020 May 30. doi:10.1186/s12941-020-00368-w
de Castro CG Jr, Gregianin LJ, Burger JA. Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leuk Lymphoma. 2020;61(10):2536-2537. doi:10.1080/10428194.2020.1786559
Van Rensburg R, Decloedt EH, Reuter H, Parker A, Schrueder N, Lahri S. Ivermectin for COVID-19: Promising but not yet conclusive. S Afr Med J. 2021;111(3):13187. doi:10.7196/SAMJ.2021.v111i3.15522
Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2021;7(7):CD015017. Published 2021 Jul 28. doi:10.1002/14651858.CD015017.pub2
Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. doi:10.1016/j.ijid.2020.11.191
Reis G, Silva EASM, Silva DCM, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med. 2022;386(18):1721-1731. doi:10.1056/NEJMoa2115869
Downloads
Additional Files
Published
Issue
Section
License
Copyright (c) 2023 Copyright (c) 2023 By the authors. This article is open access and distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) licence (https://creativecommons.org/licenses/by-nc-sa/4.0/).
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
